KIM-1 and beyond: emerging biomarkers for adjuvant immunotherapy in clear cell renal cell carcinoma
A blood protein may help identify kidney cancer patients most likely to benefit from additional immunotherapy after surgery.
This expert review proposes KIM-1 as a promising circulating biomarker for identifying patients with resected ccRCC who may benefit from adjuvant pembrolizumab, building on exploratory IMmotion010 data and current knowledge of molecular drivers. An integrative biomarker strategy is proposed, but none of the reviewed biomarkers are yet validated for routine clinical decision-making.
What the study was
- Study design
- Review
- Population
- Patients with high-risk resected clear cell renal cell carcinoma (ccRCC)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Expert Review of Molecular Diagnostics
Why it surfaced
KIM-1 as a liquid biomarker for adjuvant immunotherapy enrichment in ccRCC is an active area with trial implications (IMmotion010, KEYNOTE-564 contextually relevant). Review quality limited by lack of prospective validation data, but fills a meaningful clinical gap in adjuvant therapy decision-making.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.